{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:26:11Z","timestamp":1761895571845},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.endonu.2012.07.008","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T21:46:09Z","timestamp":1349127969000},"page":"599-605","source":"Crossref","is-referenced-by-count":2,"title":["Nuevas perspectivas en el tratamiento farmacol\u00f3gico de la enfermedad de Cushing"],"prefix":"10.1016","volume":"59","author":[{"given":"Mar\u00eda-Jos\u00e9","family":"Barahona Constanzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"del Pozo Pic\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endonu.2012.07.008_bib0005","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0010","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","article-title":"Late recurrences of Cushing's disease after initial successful transphenoidal surgery","volume":"93","author":"Patil","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1575-0922(09)70983-0","article-title":"Tratamiento farmacol\u00f3gico y seguimiento del s\u00edndrome de Cushing","volume":"56","author":"Leal-Cerro","year":"2009","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.endonu.2012.07.008_bib0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","article-title":"Ketoconazole treatment in Cushing's syndrome: experience in 34 patients","volume":"35","author":"Sonino","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.07.008_bib0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-0760(94)90267-4","article-title":"Therapy of Cushing's syndrome with steroid biosynthesis inhibitors","volume":"49","author":"Engelhardt","year":"1994","journal-title":"J Steroid biochem Mol Biol"},{"key":"10.1016\/j.endonu.2012.07.008_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2265.2012.04424.x","article-title":"A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing'syndrome","author":"Valassi","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.07.008_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000314292","article-title":"Medical treatment of Cushing's syndrome: adrenal-bloking drugs and ketaconazole","volume":"92","author":"Feelders","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome","volume":"35","author":"Verheist","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.07.008_bib0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1517\/14728210903413522","article-title":"Drugs in the medical treatment of Cushing's syndrome","volume":"14","author":"Schteingart","year":"2009","journal-title":"Expert Opin Emerging Drugs"},{"key":"10.1016\/j.endonu.2012.07.008_bib0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/TCRM.S12952","article-title":"Treatment of Cushing disease: overview and recent findings","volume":"6","author":"Mancini","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.endonu.2012.07.008_bib0055","first-page":"2","article-title":"Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11\u00df-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study","author":"Bertagna","year":"2012","journal-title":"Abstract International and European Congress of Endocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000088587","article-title":"Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease","volume":"64","author":"Greenig","year":"2005","journal-title":"Horm Res"},{"key":"10.1016\/j.endonu.2012.07.008_bib0065","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazol combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenick\u00fd","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000079048","article-title":"Somatostatin receptors in pituitary function, diagnosis and therapy","volume":"32","author":"Hofland","year":"2004","journal-title":"Front Horm Res"},{"key":"10.1016\/j.endonu.2012.07.008_bib0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.mce.2007.10.015","article-title":"Somatostatin and somatostatin receptors in Cushing","volume":"286","author":"Hofland","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.endonu.2012.07.008_bib0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.07.008_bib0085","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/endo-110-4-1147","article-title":"Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture","volume":"110","author":"Schonbrunn","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0090","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"Suppl. 1","key":"10.1016\/j.endonu.2012.07.008_bib0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000314352","article-title":"Medical treatment of Cushing's disease: somatostatin analogues and pasireotide","volume":"92","author":"Pedroncelli","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0100","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocoticotropin secretion in human corticotroph pituitary adenomas","volume":"9","author":"Batista","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0105","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.endonu.2012.07.008_bib0110","first-page":"P1406","article-title":"Pasireotide treatment is associated with improvements in hypertension: 12-month results from a large phase III study in Cushing\u2019 disease","volume":"29","author":"Pivonello","year":"2012","journal-title":"Abstract International and European Congress of Endocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0115","first-page":"P1408","article-title":"Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing's disease: results from a large randomized, double-blind phase III phase trial","volume":"29","author":"Webb","year":"2012","journal-title":"Abstract International and European Congress of Endocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0120","first-page":"P3","article-title":"Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers","author":"Henry","year":"2011","journal-title":"Abstract ENDO"},{"key":"10.1016\/j.endonu.2012.07.008_bib0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0130","first-page":"P1405","article-title":"Long-term use of pasireotide in Cushing disease: 24-month safety results from a randomized phase III study","volume":"29","author":"Bertherat","year":"2012","journal-title":"Abstract International and European Congress of Endocrinology"},{"issue":"Suppl. 1","key":"10.1016\/j.endonu.2012.07.008_bib0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000317716","article-title":"Medical Treatment in Cushing's Syndrome: dopamine agonist and cabergoline","volume":"92","author":"Petrossians","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","article-title":"Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome","volume":"10","author":"De Bruin","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.endonu.2012.07.008_bib0145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jcem-54-2-286","article-title":"Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion","volume":"54","author":"Lamberts","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0150","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agoints cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.endonu.2012.07.008_bib0165","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazol in Cushing's disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2012.07.008_bib0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11154-008-9080-6","article-title":"Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas","volume":"10","author":"Labeur","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.endonu.2012.07.008_bib0175","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","article-title":"Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas","volume":"8","author":"Haney","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.endonu.2012.07.008_bib0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease","volume":"151","author":"Ambrosi","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.07.008_bib0185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","article-title":"Effect of protracted treatment with rosiglitazone, a PPAR gamma agonist, in patients with Cushing's disease","volume":"64","author":"Giraldi","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.07.008_bib0190","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","article-title":"Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease","volume":"90","author":"Suri","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0195","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristona in Cushing syndrome","volume":"160","author":"Castinetti","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.07.008_bib0200","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1210\/jc.86.8.3568","article-title":"Successful long-term treatment of refractory Cushing disease with high-dose mifepristone (RU 486)","volume":"86","author":"Chu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.07.008_bib0205","first-page":"1","article-title":"Successful long-term treatment of Cushing's disease with mifepristone (RU486)","volume":"22","author":"Basina","year":"2012","journal-title":"Endocr Pract"},{"issue":"Suppl. 1","key":"10.1016\/j.endonu.2012.07.008_bib0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000314224","article-title":"Medical treatment of Cushing syndrome: glucocorticoid receptor antagonists and mifepristone","volume":"92","author":"Castinetti","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.endonu.2012.07.008_bib0215","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092212002392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092212002392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T11:51:39Z","timestamp":1542714699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1575092212002392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1575092212002392"],"URL":"https:\/\/doi.org\/10.1016\/j.endonu.2012.07.008","relation":{},"ISSN":["1575-0922"],"issn-type":[{"value":"1575-0922","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}